High-rolling investors have positioned themselves bearish on Moderna MRNA, and it’s important for retail traders to take note.
This activity came to our attention today through Benzinga’s tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in MRNA often signals that someone has privileged information.
Today, Benzinga’s options scanner spotted 10 options trades for Moderna. This is not a typical pattern.
The sentiment among these major traders is split, with 20% bullish and 80% bearish. Among all the options we identified, there was one put, amounting to $33,400, and 9 calls, totaling $311,248.
Projected Price Targets
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $100.0 to $105.0 for Moderna over the recent three months.
Insights into Volume & Open Interest
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Moderna’s options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Moderna’s whale trades within a strike price range from $100.0 to $105.0 in the last 30 days.
Moderna Call and Put Volume: 30-Day Overview
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MRNA | CALL | SWEEP | BULLISH | 05/17/24 | $9.45 | $9.1 | $9.37 | $100.00 | $62.7K | 994 | 853 |
| MRNA | CALL | SWEEP | NEUTRAL | 05/17/24 | $8.85 | $8.2 | $8.56 | $100.00 | $57.3K | 994 | 60 |
| MRNA | PUT | TRADE | BULLISH | 05/17/24 | $7.2 | $6.7 | $6.68 | $105.00 | $33.4K | 1.8K | 0 |
| MRNA | CALL | SWEEP | BEARISH | 04/19/24 | $5.4 | $4.55 | $4.87 | $100.00 | $32.6K | 2.4K | 853 |
| MRNA | CALL | SWEEP | NEUTRAL | 05/17/24 | $9.3 | $8.8 | $9.05 | $100.00 | $27.1K | 994 | 760 |
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm’s mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
After a thorough review of the options trading surrounding Moderna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Where Is Moderna Standing Right Now?
- With a trading volume of 180,681, the price of MRNA is down by -0.1%, reaching $103.69.
- Current RSI values indicate that the stock is is currently neutral between overbought and oversold.
- Next earnings report is scheduled for 15 days from now.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, Benzinga Pro gives you real-time options trades alerts.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.